Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: Analysis of MRI responses to treatment and correlation with NAb

Pierangelo Barbero, M. Bergui, E. Versino, A. Ricci, J. J. Zhong, B. Ferrero, M. Clerico, A. Pipieri, E. Verdun, L. Giordano, L. Durelli, A. Cussi, M. L. Genesia, E. Festa, G. Contessa, A. Ghezzi, M. Zaffaroni, R. Cavallo, F. Salvi, C. ScandellariS. Stecchi, M. G. Benedetti, G. Moretto, A. Fiumani, E. Montanari, L. Ludovico, I. Pesce, A. Tartaglione, R. C. Parodi, M. Nobile, U. Morino, F. Giuliani, E. Pucci, E. Cartechini, C. Taus, R. Urciuoli, M. Giulietti, L. Motti, G. Meola, S. Radice, M. Robotti, V. Toso, F. Bortolon, A. Milanise, L. La Mantia, E. Morgando, A. Di Sapio

Research output: Contribution to journalArticle

Abstract

Background: In RRMS, clinical exacerbations are usually associated with different types of active lesions at MRI, including: hyperintense lesions on T1-weighted post-gadolinium sequences; new hyperintense lesions or enlarging old lesions on PD/T2-weighted scans; or new hypointense lesions on T1-weighted pre-Gd sequences. Objective/methods: Primary outcome was the occurrence of patients with at least one active MRI lesion of the different types indicated above during treatment with 250 μg every other day (EOD) interferon beta (IFNP)-1b or 30 μg once weekly (OW) IFNβ-1a in outpatients with RRMS (INCOMIN Trial). Results: The number of patients with at least one 'active' lesion, evaluated over the two-year follow-up, was significantly (P = 0.014) lower in the EOD IFNβ-1b arm (13/76, 17%) then in the OW IFNβ-1a arm (25/73, 34%). NAb frequency over two-year follow-up was 22/65 (33.8%) in the EOD IFNβ-1b arm and 4/62 (6.5%) in the OW IFNβ-1a arm, significantly greater in the EOD-IFNβ-1b arm. Conclusions: The development of MRI active lesions is strongly reduced by EOD-IFNβ-1b compared with OW-IFNβ-1a, indicating that EOD-IFNβ-1b is more effective than OW-IFNβ-1a in reducing ongoing inflammation and demyelination in MS. Logistic regression showed that NAb status did not affect the risk of MRI activity.

Original languageEnglish
Pages (from-to)72-76
Number of pages5
JournalMultiple Sclerosis Journal
Volume12
Issue number1
DOIs
Publication statusPublished - Feb 2006

    Fingerprint

Keywords

  • Burden of disease (BOD)
  • Interferon beta dose
  • Interferon beta-1a
  • Interferon beta-1b
  • Magnetic resonance imaging (MRI)
  • MRI active lesions
  • Neutralizing antibodies to interferon beta (NAb)
  • Relapsing-remitting multiple sclerosis (RRMS)

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Barbero, P., Bergui, M., Versino, E., Ricci, A., Zhong, J. J., Ferrero, B., Clerico, M., Pipieri, A., Verdun, E., Giordano, L., Durelli, L., Cussi, A., Genesia, M. L., Festa, E., Contessa, G., Ghezzi, A., Zaffaroni, M., Cavallo, R., Salvi, F., ... Di Sapio, A. (2006). Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: Analysis of MRI responses to treatment and correlation with NAb. Multiple Sclerosis Journal, 12(1), 72-76. https://doi.org/10.1191/135248506ms1247oa